Company Profile // May 2012

Transcription

1 Company Profile // May

2 Disclaimer This presentation has been prepared for the group of companies held by Clal Biotechnology Industries Ltd. (CBI or the Group ) and is provided to you solely for your information and is not to be copied or distributed to any other person. This presentation does not purport to be all-inclusive or to contain all of the information that may be relevant in making any decision concerning an investment in the securities of the Group. No representation or warranty, express or implied, is made by any person as to the accuracy or completeness of the information contained herein. In particular, no representation or warranty is given as to the achievement of reasonableness of any forecasts about the future prospects of the Group. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this presentation nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. 2

3 About Us Established as an active investment company in 1998 Publicly traded on Tel Aviv Stock Exchange (TASE: CBI). Market Cap - $550M Shareholders: Clal Industries & Investments (57%), Teva (14%) Focus: Advanced clinical stages of innovative drug development Investments: $800M invested in portfolio companies ($200M by CBI) to date Current portfolio: 12 diversified investments Pipeline: Blockbuster sales potential State of the art R&D facility and production plant CBI Shareholders Public 28% Teva 14% CII 57% 3

4 Diversified Portfolio: Stages % Company Preclinical Phase I Phase II Phase III Market 38% Polyheal Sales 52% MediWound Registration 84% Andromeda Confirmatory 22% Gamida Cell Confirmatory /SPA 12% 47% 32% 23% 25% CureTech D-Pharm BioCancell Avraham Biokine 15% ProtAb 31% VacciGuard 33% Iluten 4

5 Diversified Portfolio: Therapeutic Clusters Wound Care CNS CNS Oncology Immunology Medical Devices 5

6 Management Team Management Industry Network Avi Fischer, Chairman Ruben Krupik, CEO Prof. Gabi Barabash (Sourasky Medical Center) Dr. Aharon Schwartz (Teva) Ofer Gonen, Vice President Ofer Goldberg, Vice President Amos Bankirer, Vice President Gil Milner, CFO Technology specialists Top scientists KOLs/ Physicians Pharma and Biotech executives Patent & corporate lawyers GamidaCell Andromeda Mediwound Andromeda Aposense Colbar BioControl TransPharma D-Pharm Polyheal Mediwound CureTech TransPharma CBI Biomedical MTRE Remon BioControl IPO Pharma M&A 6

7 Financials 300% TA 100 index, Biomed index, Blue-tech 50 index Long term out performance vs. benchmark Market Cap - $550M No debt 250% 200% 150% 100% 50% 0% Clal Biotechnology NASDAQ Bio TA-100 TASE Biomed (M $) Profit Liquid Assets Shareholders Equity R&D Market Cap

8 Autoimmune Diseases Andromeda (84%) DiaPep277 : Novel immunotherapeutic agent for Type 1 Diabetes Blockbuster potential Technology: Hsp60 derived peptide immune modulates the immune system Strategic deal with Teva: Covers R&D + milestones (>$100M) + 20% royalties Phase III Europe (457 patients) - primary and clinical endpoints achieved significant preservation of C-peptide levels (23% between the groups, p=0.037) Improved diabetic control measured by HbA1c levels (45.5% vs. 35.7%, p=0.035) Phase Confirmatory Phase III (global) On-going (450 patients, 120 centers) 8

9 Wound Care Mediwound (52%) NexoBrid : Treatment of severe burns, potential market $500M Technology: Enzymatic eschar removal Phase III completed successfully (175 patients) rapid eschar removal (0.8 days vs. 6.7 days, p<0.0001) reduction in wound area surgically excised (13.1% vs. 56.7%, p<0.0001) Registration process in EU. Phase III in the US to begin shortly Polyheal (38%) PolyHeal : Treating hard to heal wounds, potential market $500M Technology: Charged microspheres Successful and significant clinical results (>250 patients) creation of granulation tissue (46.9% vs. 15.4%, p<0.02) reduction of wound size (-39% vs %, p<0.03) EU launch in 2012 Strategic partnership between Teva, Mediwound and Polyheal: Teva covers all R&D + milestones (>$300M) + royalties 9

10 Oncology CureTech (12%) CT-011 : An antibody for several types of cancer diseases Technology: Immune-modulating antibody Collaboration agreement with Teva: R&D + milestones ($250M) + 6% royalties 6 Phase II studies on-going (>400 patients) Lymphoma (DLBCL) results: reduced rate of progression (PFS 69% vs. 58%) and improved survival (OS 85% vs. 69%) Gamida Cell (22%) StemEx : Cell therapy in the area of bone marrow transplantation Technology: Expansion of stem cells derived from umbilical cord blood Pivotal Phase III study under SPA, 100 patients, Open label, Fast track 10

11 Value Creating Milestones Medical Device Fund Launch Andromeda Phase III Results MediWound EU Marketing Approval Gamida Cell Phase III Results Avraham Phase II - MCI Initiation Biokine Phase II Initiation Thrombotech Phase II Results PiR Squared First in Man Q42011 Q12012 Q22012 Q32012 Q42012 Q12013 Q22013 Avraham Phase II - AD Interim results BioCancell Phase II Initiation BioCancell Phase II Results CureTech Phase II Results ProtAb Phase I Initiation CureTech Strategic Deal with Teva D-Pharm Phase III Interim Results MediWound Phase III Initiation CureTech Phase III Initiation Significant Milestone Milestone 11

12 Clal Biotechnology Industries Summary Portfolio Companies Phase III Compounds Pipeline Products $M Liquidity $M Medical Device Fund 12